Love Pharma Inc Statistics
Love Pharma Inc (JOLT.X) Stock Statistics & Valuation Metrics
Total Valuation
Love Pharma Inc has a market cap or net worth of CAD 190.93K. The enterprise value is CAD 861.03K.
- Market Cap
- CAD 190.93K
- Enterprise Value
- CAD 861.03K
Share Statistics
Love Pharma Inc has 12,728,754 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 12,728,754
- Owned by Insiders
- 18.41%
- Owned by Institutions
- ―
Financial Efficiency
Love Pharma Inc’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Love Pharma Inc had revenue of ― and earned 43.78K in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- 0
- Operating Income
- -63.71K
- Pretax Income
- ―
- Net Income
- 43.78K
- EBITDA
- -63.71K
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- -0.77
- 52-Week Price Change
- -81.25%
- 50-Day Moving Average
- 0.02
- 200-Day Moving Average
- 0.06
- Relative Strength Index (RSI)
- 22.46
- Average Volume (3m)
- 79.93K
Important Dates
Love Pharma Inc upcoming earnings date is May 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- May 03, 2027
- Ex-Dividend Date
- ―
Balance Sheet
Love Pharma Inc has ― in cash and marketable securities with CAD 0.00 in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- CAD 0.00
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Love Pharma Inc is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 83.38%

